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Skin diffusate samplesAbstract An isocratic RP-HPLC–UV method for the analysis of voriconazole in skin diffusate
samples has been developed and validated. Experimental design was employed to optimize the
method. The method was validated as per ICH guidelines. Linearity was observed over the concen-
tration range of 2–100 lg mL1 (r2 = 0.999). Limits of detection and quantiﬁcation were 0.6 and
2 lg mL1, respectively. Intra-day and inter-day precision (% RSD) was within the ICH limits
(62%). The method was successfully used to analyze skin diffusate samples, and the effectiveness
of different permeation enhancers was compared with respect to ﬂux and permeability coefﬁcient.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Voriconazole (VCZ), a derivative of ﬂuconazole, is a second-
generation triazole that has improved antifungal activity
against Aspergillus, Fusarium, Pseudallescheria boydii,
Penicillium marneffei, and ﬂuconazole-resistant Candida
species (Craig and Stitze, 2004; Brunton et al., 2006). Further-more, VCZ is one of the few drugs active against Scedosporium
apiospermum (Scott and Simpson, 2007). VCZ is derived from
the structure of ﬂuconazole by replacement of one triazole
moiety by a ﬂuoropyrimidine group and alpha methylation
(Perea et al., 2000). VCZ is designated chemically as (2R,3S)-
2-(2,4-diﬂuorophenyl)-3-(5-ﬂuoro-4-pyrimidinyl)-1-(1H-1,2,4-
triazol-1-yl)-2-butanol (Fig. 1) and having a molecular weight
of 349.31. Compared to ﬂuconazole, VCZ has an enhanced
antifungal spectrum that includes ﬁlamentous fungi. VCZ
inhibits ergosterol synthesis by interacting with 14-alpha
demethylase, a cytochrome P-450 (CYP) enzyme that is needed
to convert lanosterol into ergosterol, an essential component
of the cell membrane (Sweetman, 2009). VCZ is commercially
available as lyophilized powder for preparing a solution for
intravenous infusion, as a ﬁlm coated tablet for oral adminis-
Figure 1 Chemical structure of voriconazole.
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There is no topical formulation of VCZ till today for the
treatment of local or non-systemic fungal infections but the
use of topical antifungal therapy has been reported sporadi-
cally in the literature (Klein and Blackwood, 2006; Pyle
et al., 2010). Topical VCZ solution combined with systemic
antifungal therapy is a viable treatment for cutaneous aspergil-
losis (Klein and Blackwood, 2006). The present investigation
may be useful for the development of VCZ topical formula-
tion. In this study we used three penetration enhancers to test
the permeability of VCZ through rat skin.
Penetration enhancers are those compounds that increase
drug penetration through skin’s barrier membrane by interact-
ing with certain components of the skin. They increase the ﬂuid-
ity of the intercellular lipid lamellae and cause the stratum
corneum to swell and/or leach out someof the structural compo-
nents, thus increasing drug permeation through the barrier
membrane (Hadgraft, 1984). Alcohols are commonly used in
many transdermal formulations, and ethanol is often the solvent
of choice for use in patches (Williams and Barry, 2004). Ethanol
has been used to enhance the ﬂux of levonorgestrel, estradiol,
hydro-cortisone and 5-ﬂuorouracil through rat skin (Friend
et al., 1988) and of estradiol through the human skin in vivo (Per-
shing et al., 1990). Dimethylsulfoxide (DMSO) is one of the ear-
liest and most widely studied penetration enhancers. It is a
powerful aprotic solvent which hydrogen bonds with itself
rather than with water. A vast array of literature describes the
penetration enhancing activities of DMSO, and studies have
shown it to be effective in promoting both hydrophilic and lipo-
philic permeants (Kligman, 1965). Usually surfactants are
added to formulations in order to solubilize lipophilic ingredi-
ents. Therefore, they have been potential to solubilize lipids
within the stratum corneum. Surfactants have also been shown
to enhance the ﬂux of permeants across biological membranes
(Tupker et al., 1990). It has been well-researched and reported
that the surfactants facilitate the permeation of many drugs
through skin membranes. Sodium lauryl sulfate (SLS) has
shown a signiﬁcant enhancement of chloramphenicol through
hairless mouse skin (Sarpotdar and Zatz, 1986). Eucalyptus
oil is an effective skin penetration enhancer, and it contains
1,8-cineole, a monoterpene cyclic ether, which can enhance pen-
etration of both lipophilic and hydrophilic compounds (Wil-
liams and Barry, 1989; Yamane et al., 1995; Femenia-Font
et al., 2005; Narishetty and Panchagnula, 2005; Biruss et al.,
2007). 1,8-cineole binds to the stratum corneum and enhances
lipophilic drug penetration by increasing the partition coefﬁ-
cient and hydrophilic drug penetration by increasing the diffu-
sion coefﬁcient (Cornwell et al., 1996; Cal et al., 2001). 1,8-
cineole has been found to increase skin penetration by disrupt-ing intercellular lipids in subcutaneous membrane and changing
its ﬂuidity (Yamane et al., 1995; Cornwell et al., 1996; Gao and
Singh, 1997; Narishetty and Panchagnula, 2005; Williams et al.,
2006; Anjos et al., 2007). Eucalyptus oil also has a broad spec-
trum of antimicrobial activity, and this property has been well
utilized in therapeutics (Warnke et al., 2006)
There are various HPLC methods available for the estima-
tion of VCZ in pharmaceutical and biological matrices
(Stopher and Gage, 1997; Gage and Stopher, 1998; Ferretti
et al., 1998; Perea et al., 2000; Pennick et al., 2003; Pehourcq
et al., 2004; Hariprasad et al., 2004; Khoschsorur et al., 2005;
Adams and Bergold, 2005; Langman and Boakye-
Agyeman, 2007; Cheng et al., 2007; Li et al., 2007; Srinubabu
et al., 2007; Chhun et al., 2007; Pascual et al., 2007; Wenk
et al., 2006; Nagarjuna et al., 2007; Prajapati et al., 2008;
Simmel et al., 2008; Michael et al., 2008; Nakagawa et al.,
2008; Vorwerk et al., 2008; Khetre et al., 2009; Gu and Li,
2009; Gordien et al., 2009; Kahle et al., 2009; Gowrisankar
et al., 2009; Steinmann et al., 2011). Themain purpose of this re-
searchwas to develop and validate an isocratic RP-HPLCmeth-
od for the quantitative analysis of VCZ in skin diffusate samples
as well as to evaluate the enhancing effects of three penetration
enhancers, i.e., DMSO, 1% SLS, and eucalyptus oil on the per-
cutaneous absorption of VCZ through rat skin in vitro.
2. Materials and methods
2.1. Chemicals, reagents and solutions
Pharmaceutical grade VCZ was gifted by Hetero Drugs Pvt
Ltd. (Hyderabad, India). Methanol and acetonitrile (HPLC
grade) were purchased from Merck Chemical Company
(India). Potassium dihydrogen orthophosphate, and triethyl-
amine used were analytical grade and purchased from S D
Fine Chem. Ltd. (Mumbai, India). AR grade of DMSO,
SLS and eucalyptus oil were purchased from Sigma Aldrich
(Bengaluru, India). Standard stock solution of VCZ was pre-
pared in methanol at a concentration of 1.0 mg mL1 and fur-
ther diluted with methanol to furnish working standard stock
solution of 100 lg mL1. The working standard stock solution
was used to prepare calibration samples. Buffer was prepared
by dissolving 2720 mg (20 mM) of potassium dihydrogen
phosphate in 1 L of HPLC grade water; pH was adjusted to
6.0 with triethylamine. Phosphate buffer saline (PBS) used
composed of 0.8% w/v of sodium chloride, 0.02% w/v of
potassium chloride, 0.144% w/v of di-sodium hydrogen phos-
phate and 0.024% w/v of potassium dihydrogen phosphate.
Finally, pH was adjusted to 7.4 with 1N sodium hydroxide.
2.2. HPLC instrumentation and chromatographic conditions
The HPLC system consisted of quaternary pumps (model
Perkin Elmer series 200 HPLC pump), auto sample injecting
system, and temperature controlled column oven. The UV–
vis detector (model Perkin Elmer series 200 UV–vis detector)
was operated at a wavelength of 255 nm. The software used
was Total Chrome version 6.58. Columns used were C18,
250 mm · 4.6 mm, 5.0 lm, (Dr. Maisch GmbH, Germany),
Lichrospher C18, 250 mm · 4.6 mm, 5.0 lm (Merck, Germany)
and Atlantis C18, 250 mm · 4.6 mm, 5.0 lm (Waters Corpora-
tion, USA).
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temperature of 25 ± 2 C using a Dr. Maisch, RP C18
(250 mm · 4.6 mm, 5 lm) analytical column; the mobile phase
consisted of acetonitrile–potassium dihydrogen orthophos-
phate buffer (pH 6.0, adjusted with triethylamine; 20 mM)
(55:45, v/v) at a ﬂow rate of 1.0 mL min1. Before use, the
mobile phase was ﬁltered through a 0.22 lm nylon membrane
ﬁlter and sonicated for 15 min. Injection volume was 20 lL in
all experiments.
2.3. Construction of the calibration curve
The working standard stock solution was diluted with mobile
phase to prepare calibration samples in the concentration
range of 2–100 lg mL1. Triplicate injections of 20 lL were
made for each calibration sample and chromatographed under
the speciﬁed HPLC conditions. Peak area was plotted against
the corresponding concentration to obtain the calibration
graph.
2.4. Determination of drug solubility
The saturation solubility of VCZ was determined in distilled
water, pH 7.4 phosphate buffer saline solution containing 1%
SLS (1% SLS PBS) and the individual donor vehicles. Analysis
was carried out by placing an excess of the drugwith 1 mL of the
appropriate solvent in 1.5 mL sealed polypropylenemicro-vials,
shaking on a water bath at 37 C for 48 h until equilibrium was
achieved. The suspension was centrifuged at 4000 rpm for
15 min, passed through a membrane ﬁlter (0.45 lm), and was
quantiﬁed for VCZ by HPLC with reference to a calibration
curve after appropriate dilution with methanol when necessary.
The experiments were performed in triplicate.
2.5. Permeation studies
A diffusion apparatus with a diffusional surface area of
2.76 cm2 having receptor volume of 7 mL was used for carry-
ing out the permeation studies. The abdominal portion
(1 mm thickness) of the albino rat skin was taken and neatly
shaved to remove the hair. Prior to mounting, the skin was
soaked in 1% SLS PBS for 30 min. The skin was mounted
between the compartments of diffusion cell with stratum cor-
neum facing donor compartment and clamped into position.
1 mL of 10 mg mL1 methanolic solution of VCZ was mixed
with 1 mL of each permeation enhancer (DMSO, 1% SLS
and eucalyptus oil) and placed in donor compartment. Recep-
tor compartments were ﬁlled with medium (1% SLS PBS), and
the diffusion cells were placed on a magnetic stirrer with stir-
ring bars at a speed of 400 rpm. The study was conducted at
a temperature of 37 C. Samples were collected from each
apparatus after 0.5, 1, 2, 3, 4, 5, 6 and 22 h. Each time,
1 mL of the receptor medium was withdrawn at predetermined
time points, and the receptor compartments were replaced with
the same amount of the fresh medium.
2.6. Sample preparation
To the collected receptor medium, 1 mL of methanol was
added, centrifuged for 15 min at 4000 rpm. 1 mL of the super-natant was taken, ﬁltered through 0.22 lm syringe ﬁlter and
triplicate injections of 20 lL were made for each sample into
HPLC.
2.7. Data analysis for skin permeation
The amount of drug permeating through the skin during a
sampling interval was calculated based on the measured recep-
tor-phase concentration and volume. The cumulative amount
of drug permeating per unit area versus time was plotted.
The data were calculated and presented as mean ± SD
(n= 3). The steady-state ﬂux (Jss) and permeability coefﬁcient
(P) were calculated by using Eqs. (1) and (2) (Barry, 1983).
Jss ¼ dQ
dt
 
ss
1
A
ð1Þ
P ¼ dQ
dt
 
ss
1
A
1
C0
ð2Þ
where A is the effective diffusion area; Co, the initial drug con-
centration in donor compartment and (dQ/dt)ss is the steady-
state slope.
3. Results and discussion
3.1. Drug solubility
VCZ, the structure of which is shown in Fig. 1, has a molecular
weight (MW) of 349.31. Its solubility in water and 1% SLS
PBS was 24.49 ± 1.14 lg mL1 and 11.03 ± 0.56 mg mL1,
respectively. Since VCZ has a low solubility in water, 1%
SLS PBS was used as receptor media to increase solubility
and maintain the sink conditions during the experiments.
The saturation solubility(Cs) of VCZ in methanol was found
to be 266.29 ± 4.14 mg mL1, similarly in 1:1 methanolic mix-
tures of DMSO, SLS and eucalyptus oil was found to be
276.01 ± 4.29, 30.15 ± 0.75 and 183.42 ± 2.16 mg mL1,
respectively.
3.2. Method development and optimization
Wave length of 255 nm was selected for the HPLC study,
which is the absorption maximum of VCZ. The chromato-
graphic method was optimized by changing various parame-
ters such as composition of organic phase in mobile phase
and pH of the buffer. Initially the mobile phase used was a
mixture of acetonitrile–water (40:60, v/v).VCZ was eluted with
high capacity factor (5.35) and tailing factor (4.44). To reduce
the capacity factor as well as tailing factor acetonitrile (organic
phase) concentration was increased to 70% v/v, which results
in tailing factor of 1.82 and capacity factor of 1.22.
Voriconazole is a weak base having pKa of 1.76 and neutral
over the majority of the pH range (Theurillat et al., 2010),
hence water was replaced with potassium dihydrogen ortho-
phosphate buffer (20 mM). In order to get a satisfactory
capacity factor (2–3) as well as tailing factor (62.0), we varied
pH of buffer and % (v/v) of organic phase employing full fac-
torial design (two factors at three levels), keeping pH of buffer
at three levels (5.0, 6.0 and 7.0) and % v/v of organic phase at
three levels (40, 55 and 70% v/v) consisted of total of nine (32)
4 M. Vamsi Krishna et al.runs. Based on the performed experiments, coefﬁcients were
calculated characterizing the polynomes of second order and
response surface graphs were constructed. Experimental
results were computed by statistica version 6.0. The equation
for capacity factor obtained was:
z ¼ 7:903þ 2:3883x 0:3617y 0:1433x2  0:007xy
þ 0:0026y2 ð3Þ
where x is the pH, y is the% (v/v) of organic phase of the
mobile phase and z is the capacity factor for VCZ. The
response surface plot is presented in Fig. 2.
The equation for tailing factor obtained was:
z ¼ 35:2776 8:8792x 0:2076y 0:7383x2  0:0012xy
þ 0:0013y2 ð4Þ
where x is the pH, y is the % (v/v) of organic phase of the
mobile phase and z is the tailing factor for VCZ. The response
surface plot is presented in Fig. 3.
The model was validated by the analysis of variance
(ANOVA) (Table 1). The statistical analysis showed that the
model represents the phenomenon quite well and the variation
of the responses (capacity factor and tailing factor) was cor-
rectly related to the variation of the factors (pH of buffer
and % v/v of organic phase), showing a good agreement be-
tween experimental and predicted values for capacity factor
(Fig. 4) as well as for tailing factor (Fig. 5). The predicted
correlation coefﬁcients were in reasonable agreement with
the adjusted correlation coefﬁcients for both capacity factor
and tailing factor. Overall quality of ﬁt was considered good
as the adjusted correlation coefﬁcient values for model were
higher than 0.90.
The observed lowest P-value (0.001) and highest F-value
(52.09) (F> P value) for % (v/v) organic phase (Table 1) in-Figure 2 Response surface plot showing effect of pH and % (v/v) o
organic phase and Z axis-capacity factor).deed suggested that this is the most important factor affecting
capacity factor. In addition, a lower p value (0.006) along with
higher F value (24.03) indicates, the signiﬁcant effect of %
(v/v) organic phase upon tailing factor.
Analyzing the obtained three-dimensional graphs, optimal
chromatographic conditions were deﬁned according to
response and peak symmetry. Optimal conditions for the
separation of VCZ were obtained using Dr. Maisch GmbH
C18, (250 mm · 4.6 mm, 5.0 lm) column with mobile
phase consisted of acetonitrile–potassium dihydrogen
orthophosphate (pH 6; 20 mM) (55:45, v/v) at a ﬂow rate of
1.0 mL min1. These chromatographic conditions achieved rea-
sonable retention (k= 2.02) and tailing factor 1.15 (Fig. 6). No
interference from the blank, vehicles and endogenous sub-
stances was observed (Fig. 6) at the retention time of VCZ.
3.3. Solution stability
The stability of VCZ in mobile phase was investigated by ana-
lyzing the standard of VCZ (60 lg mL1) at 0, 3, 6, 9, 12 and
24 h, after preparation at room temperature. No signiﬁcant
variation in the peak area of standard solution was observed
up to 24 h (% RSD, 0.48) and also no additional peak was
found in chromatogram indicating the stability of VCZ in
mobile phase.
3.4. Method validation
To conﬁrm the suitability of the method for its intended
purpose, the method was validated in accordance with the
ICH guidelines (ICH guideline Q2 (R1), 2005), for system suit-
ability, linearity, accuracy, precision, limit of detection (LOD),
limit of quantiﬁcation (LOQ), speciﬁcity and robustness.f acetonitrile upon capacity factor. (X axis-pH, Y axis-% (v/v) of
Figure 3 Response surface plot showing effect of pH and % (v/v) of acetonitrile upon tailing factor. (X axis-pH, Y axis-% (v/v) of
organic phase and Z axis-tailing factor).
Table 1 ANOVA results.
Source DF SS MS F P
ANOVA for response surface quadratic model for capacity factor
pH 2 0.5268 0.2634 1.32 0.362
% (v/v) organic phase 2 20.7146 10.3573 52.09 0.001
Error 4 0.7954 0.1988
Total 8 22.0367
S= 0.4459 Predicted r2 = 0.9639 Adjusted r2 = 0.9278
ANOVA for response surface quadratic model for tailing factor
pH 2 1.10242 0.55121 5.33 0.074
% (v/v) organic phase 2 4.97242 2.48621 24.03 0.006
Error 4 0.41384 0.10346
Total 8 6.48869
S= 0.3217 Predicted r2 = 0.9317 Adjusted r2 = 0.9089
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System-suitability test was an integral part of method develop-
ment and has been used to ensure adequate performance of the
chromatographic system. Retention time (Rt), number of
theoretical plates (N) and tailing factor (T), were evaluated
for six replicate injections of the drug at a concentration of
60 lg mL1 and were found to be 6.04 ± 0.03 (RSD= 0.5%)
min, 42842.48 ± 182.92 (RSD= 0.42%) and 1.15 ± 0.02
(RSD= 1.73%), respectively. The RSD (%) of retention time,
number of theoretical plates and the tailing factor was within
2%, indicating the suitability of the system. The number of the-
oretical plates and the tailing factor were within the acceptance
criteria of >2000 and62, respectively, indicating good column
efﬁciency and optimum mobile phase composition.
3.4.2. Linearity
Linearity is the ability of the method to elicit test results that
are directly proportional to analyte concentration within agiven range. VCZ showed linearity in the concentration range
of 2–100 lg mL1 with a correlation coefﬁcient (r2) of 0.999.
The regression equation obtained was Y= 18010X21345,
where Y is peak area and X is concentration of VCZ (lg mL
1). This equation was used to determine the amount of
VCZ present in the skin diffusate samples. The linearity of
the regression model was tested by plotting the peak area resid-
uals on the vertical axis against the corresponding concentra-
tion on the horizontal axis. The residuals are scattered
randomly around zero. Hence the linearity assumption was
not violated.
3.4.3. Accuracy
Accuracy is the measure of exactness of an analytical method,
or the closeness of agreement between the measured value and
the value that is accepted either as a conventional, true value
or an accepted reference value. Accuracy of the method was
determined by performing recovery experiments. Known
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Figure 4 Experimental capacity factors versus predicted.
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Figure 5 Experimental tailing factors versus predicted.
6 M. Vamsi Krishna et al.amount of the standard at 80% (40 lg), 100% (50 lg) and
120% (60 lg) levels was fortiﬁed to the mixture of skin diffu-
sate samples. Peak area of the standard was calculated by tak-
ing the difference between peak area of fortiﬁed and
unfortiﬁed samples. Three replicate samples of each concentra-
tion level were prepared and the percentage recovery at each
level (n= 3) was determined. Percentage recovery at 80%,
100% and 120% levels was 100.4, 100.02 and 100.16,respectively. The results obtained are in good agreement with
the added amounts of the standard.
3.4.4. Precision
The precision of an analytical procedure expresses the close-
ness of agreement between a series of measurements obtained
from multiple sampling of the same homogeneous sample
under the prescribed conditions. Intra-day and inter-day preci-
Methanol
Standard (30µg/ml)
1% SLS : Methanol (1:1)
DMSO: Methanol (1:1)
Blank
0.0 0.5 1.0 1.5 2.0 2.5 3.0 3.5 4.0 4.5 5.0 5.5 6.0 6.5 7.0 7.5 8.0 8.5 9.0 9.5 10.0 10.5 11.0 11.5 12.0 12.5 13.0 13.5 14.0 14.5
Eucalyptus oil : Methanol (1:1)
Figure 6 Overlaid chromatograms of VCZ blank, standard and 12 h diffused samples from methanol, eucalyptus oil: methanol (1:1),
DMSO: methanol (1:1) and 1% SLS: methanol (1:1).
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(10, 40, 60, and 80 lg mL1) of VCZ. For intra-day variation,
sets of six replicates of the four concentrations were analyzed
on the same day; for inter-day variation, six replicates were
analyzed on six different days. The intra-day and inter-day
precision (% RSD) was found to be less than 2%, indicating
that the method was precise.
3.4.5. Limit of detection and limit of quantiﬁcation
The LOD was deﬁned as the lowest concentration of VCZ
resulting in a signal-to-noise ratio of 3:1 and LOQ was ex-
pressed as a signal-to-noise ratio of 10:1. Due to the difference
in detector response, different concentrations ranging from 0.1
to 3 lg mL1 were prepared and analyzed. The LOD and LOQ
values obtained were 0.6 and 2 lg mL1, respectively.
3.4.6. Speciﬁcity
Speciﬁcity is the ability to measure accurately and speciﬁcally
the analyte of interest in the presence of other components that
may be expected to be present in the sample matrix. The
speciﬁcity of the proposed HPLC method is illustrated in
Fig. 6, where complete separation of VCZ was seen in
ex vivo skin diffusate samples. The peaks of analyte were pure
and there were no endogenous peaks at the retention time ofTable 2 Permeation parameters of permeation enhancers.
Permeation enhancers (dQ/dt)ss
a
Methanol 35.74 ± 1.42
DMSO:Methanol (1:1) 62.50 ± 1.66
1% SLS:Methanol (1:1) 41.50 ± 0.89
Eucalyptus oil:Methanol (1:1) 80.54 ± 2.15
a Values are expressed as mean ± SD, n= 3.VCZ. The components of ex vivo samples did not interfere
with the analyte, thereby conﬁrming the speciﬁcity of the ana-
lytical method. The average retention time ± standard devia-
tion for VCZ was found to be 6.04 ± 0.03 min, for six
replicates. The peaks obtained were sharp and had clear base-
line separation.
3.4.7. Robustness
A method is robust if it is unaffected by small changes in oper-
ating conditions. To evaluate HPLC method robustness few
parameters were deliberately varied. The parameters included
variation of C18 columns from different manufacturers, pH
of the buffer, ﬂow rate and percentage of acetonitrile in the
mobile phase. Two analytical columns were used during the
experiment, one from Germany (Lichrospher C18 column)
and the other from USA (Atlantis C18 column). Each of
the three examined factors (pH, ﬂow rate, and acetonitrile
percentage) selected was changed one at a time to estimate
the effect. Replicate injections (n= 6) of standard solution
(10 lg mL1) were performed under small changes of chro-
matographic parameters (factors). Flow rate was varied by
1 ± 0.1 mL min1, composition of acetonitrile in mobile phase
was varied by 55 ± 2% (v/v), while pH was varied by 6 ± 0.1.
Results obtained were remained unaffected by small variationsJss (lg h
1cm2)a P · 103 (cm h1)a
12.92 ± 0.54 2.58 ± 0.14
22.59 ± 0.89 4.51 ± 0.18
15.00 ± 0.65 3.00 ± 0.11
29.11 ± 1.52 5.82 ± 0.24
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Figure 7 Effect of permeation enhancers upon permeation of VCZ. (Each point represents the mean ± SD of three determinations).
8 M. Vamsi Krishna et al.of these parameters. The results from the two columns (reten-
tion time: 6.04 ± 0.08 and 6.05 ± 0.07; tailing factor:
1.14 ± 0.03 and1.14 ± 0.04; peak area: 156520.76 ± 1536.28
and 156225.34 ± 1534 for Lichrospher and Atlantis, respec-
tively) also indicated that there is no signiﬁcant difference.
3.4.8. Application to ex vivo skin permeation study
Overlaid chromatograms of 12 h study samples are presented
in Fig. 6. The effect of different permeation enhancers on the
permeation of VCZ through rat abdominal skin was examined.
The permeation parameters are shown in Table 2, and the per-
meation proﬁles obtained are shown in Fig. 7. The steady-state
slopes (dQ/dt)ss for individual donor vehicles were calculated
from the linear portion of the curve between VCZ permeated
(lg cm2) and time (h) as shown in Fig. 7. Steady state slopes
were found to be 35.74 ± 1.42, 62.50 ± 1.66, 41.50 ± 0.89
and 80.54 ± 2.15 for methanol (vehicle), DMSO: methanol
(1:1), 1%SLS: methanol (1:1), and eucalyptus oil: methanol
(1:1), respectively. The ﬂuxes of VCZ from different perme-
ation enhancers were calculated by dividing the steady-state
slope with surface area of the skin exposed to donor compart-
ment and were found to be 12.92 ± 0.54, 22.59 ± 0.89,
15.00 ± 0.65 and 29.11 ± 1.52 lg cm2 h1 for methanol
(vehicle), DMSO: methanol (1:1), 1% SLS:methanol (1:1),
and eucalyptus oil:methanol (1:1), respectively, whereas the
amount of VCZ permeated from above donor vehicles after
22 h was 2928.36, 4021.76, 3718.62 and 5632.18 nmol, respec-
tively. Permeability coefﬁcient (P) of VCZ was calculated by
dividing ﬂuxes with initial concentration (C0). The permeabil-
ity coefﬁcient was found to be lowest {(2.58 ± 0.14) 103 cm h
1} from methanol (vehicle), whereas it was found to be high-
est {(5.82 ± 0.24) 103 cm h1} from eucalyptus oil:methanol
(1:1). Eucalyptus oil consists of 75% 1,8-cineole. Cineole is a
cyclic terpene that acts by creating liquid pools in the stratum
corneum and disrupting the lipid structure of the stratum cor-
neum, thereby increasing the diffusion coefﬁcient (Williams
and Barry, 1991). Though VCZ has low solubility in 1:1 mix-
ture of methanol and eucalyptus oil compared to 1:1 methano-lic mixtures of DMSO and 1% SLS, the permeability
coefﬁcient and the amount permeated were found to be highest
from it, indicating the potential of eucalyptus oil over DMSO
and SLS for permeation of VCZ through rat abdominal skin.
Eucalyptus oil may therefore serve as a suitable permeation
enhancer for enhancing the delivery of VCZ into the skin.
4. Conclusions
Development and validation of RP-HPLC method for the
analysis of voriconazole in the skin diffusate samples have
been described. The method was accurate, reproducible, spe-
ciﬁc and applicable to the evaluation of permeation parameters
of VCZ using three permeation enhancers (DMSO, 1% SLS
and eucalyptus oil) across rat abdominal skin. Among the per-
meation enhancers employed, eucalyptus oil was found to pro-
vide a strong permeation enhancing effect and can be used in
the formulation to enhance skin permeation of voriconazole.
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